Reuters logo
4 个月内
BRIEF-FDA grants priority review for Amgen's Blincyto supplemental biologics license application
2017年3月29日 / 晚上8点21分 / 4 个月内

BRIEF-FDA grants priority review for Amgen's Blincyto supplemental biologics license application

1 分钟阅读

March 29 (Reuters) - Amgen Inc

* FDA grants priority review for Amgen's Blincyto® (blinatumomab) supplemental biologics license application

* Amgen Inc - Prescription Drug User Fee Act (PDUFA) target action date is Aug. 14, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below